Clinical Positron Emission Tomography/Computed Tomography: Quarter-Century Transformation of Prostate Cancer Molecular Imaging

Author(s): Chen, DC; Huang, S; Buteau, JP; Kashyap, R; Hofman, MS;
Details: Publication Year 2024-04,Volume 19,Issue #2,Page 261-279
Journal Title: PET Clinics
Publication Type: Review
Abstract: Although positron emission tomography/computed tomography (PET/CT) underwent rapid growth during the last quarter-century, becoming a new standard-of-care for imaging most cancer types, CT and bone scan remained the gold standard for patients with prostate cancer. This occurred as 2-fluorine-18-fluoro-2-deoxy-d-glucose was perceived to have a limited role owing to low sensitivity in many patients. A resurgence of interest occurred with the use of fluorine-18-sodium-fluoride PET/CT as a replacement for bone scintigraphy, and then choline, fluciclovine, and dihydrotestosterone (DHT) PET/CT as prostate "specific" radiotracers. The last decade, however, has seen a true revolution with the meteoric rise of prostate-specific membrane antigen PET/CT.
Publisher: Elsevier
Keywords: Male; Humans; *Positron Emission Tomography Computed Tomography/methods; *Prostatic Neoplasms/diagnostic imaging; Fluorine Radioisotopes; Molecular Imaging; Gallium Radioisotopes; Pet; Pet/ct; Psma; Prostate-specific membrane antigen; Radiopharmaceuticals; Radiotracers
Department(s): Cancer Imaging
Publisher's Version: https://doi.org/10.1016/j.cpet.2023.12.011
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-04-02 01:32:28

Last Modified: 2024-04-02 01:32:43